January 5, 2021

HEMOPHILIA GENE THERAPY MARKET ANALYSIS

Hemophilia Gene Therapy Market - by Hemophilia Type (Hemophilia A and Hemophilia B) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Trends, and Forecast to 2026

Hemophilia is a genetic disorder in which patient’s blood do not clot normally due to lack of blood-clotting proteins known as coagulating factors. Conventional treatment options include timely replacement of the specific clotting factor. Major pharma and biotech companies are conducting research and development to develop gene therapy for hemophilia due to various shortcomings with conventional therapy. Increasing number of hemophilic patients that require treatment and strong product pipeline are expected to drive growth of the hemophilia gene therapy market.

Market Dynamics

Major factors that are driving growth of the hemophilia gene therapy market include increasing prevalence of hemophilia, issue of high cost, access to current hemophilia treatment, which includes coagulation factor VIII and IX, and increasing number of companies engaged in research and development of gene therapy products. According to the Centers for Disease Control and Prevention, hemophilia A is a rare, X-linked bleeding disorder that affects around 1 in 5,000 to 10,000 live-born males. Hemophilia B is less common than hemophilia A, with an incidence of around 1 in 25,000 births. According to 2016 global survey by the World Federation of Hemophilia, the total number of individuals with hemophilia worldwide was 184,723, including 16,949 within the U.S.

Key features of the study:

  • This report provides in-depth analysis of the global hemophilia gene therapy market and provides market size (US$ Mn) and compound annual growth rate (CAGR %) for the forecast period (2018 – 2026), considering 2017 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, pipeline analysis, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global hemophilia gene therapy market based on the following parameters – company overview, financial performance, market presence, distribution strategies, key developments and strategies, and future plans
  • Key companies covered as a part of this study include BioMarin Pharmaceuticals, Inc., Spark Therapeutics, Pfizer, Inc., UniQure NV, Ultragenyx Pharmaceutical, Shire PLC, Sangamo Therapeutics, Inc., and Freeline Therapeutics
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, product up-gradation, market expansion, and marketing tactics
  • The global hemophilia gene therapy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the hemophilia gene therapy market

Detailed Segmentation:

  • Global Hemophilia Gene Therapy Market, By Type:
    • Hemophilia A
    • Hemophilia B
  • Global Hemophilia Gene Therapy Market, By Region:
    • North America
      • By Type
        • Hemophilia A
        • Hemophilia B
      • By Country:
        • U.S.
        • Canada
    • Latin America
      • By Type
        • Hemophilia A
        • Hemophilia B
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Type
        • Hemophilia A
        • Hemophilia B
      • By Country:
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Type
        • Hemophilia A
        • Hemophilia B
      • By Country:
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Type
        • Hemophilia A
        • Hemophilia B
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Type
        • Hemophilia A
        • Hemophilia B
      • By Country:
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • BioMarin Pharmaceuticals, Inc. *
      • Company Overview
      • Product Portfolio
      • Key Highlights
      • Financial Overview
      • Market Strategies
    • Spark Therapeutics
    • Pfizer, Inc.
    • UniQure NV
    • Ultragenyx Pharmaceutical
    • Shire PLC
    • Sangamo Therapeutics
    • Freeline Therapeutics

“*” marked represents similar segmentation in other categories in the respective section.

Request the sample copy of here:

https://www.coherentmarketinsights.com/insight/request-sample/2480

Download the PDF Brochure here:

https://www.coherentmarketinsights.com/insight/request-pdf/2480

Buy now the market research report here:

https://www.coherentmarketinsights.com/insight/buy-now/2480

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions.

What we provide:

  • Customized Market Research Services
  • Industry Analysis Services
  • Business Consulting Services
  • Market Intelligence Services
  • Long term Engagement Model
  • Country Specific Analysis

Explore CMI Services here

Contact Us:

Mr. Shah

Coherent Market Insights Pvt. Ltd.

Address: 1001 4th ave, #3200 Seattle, WA 98154, U.S.

Phone: +1-206-701-6702

Email: sales@coherentmarketinsights.com

Source:

https://www.coherentmarketinsights.com/market-insight/hemophilia-gene-therapy-market-2480